Media Information

We appreciate your interest in covering the 2023 Association for Molecular Pathology (AMP) Annual Meeting & Expo. With more than 200 exhibiting companies, 60 educational sessions, nearly 400 poster presentations, and 2,900+ attendees, the AMP Annual Meeting & Expo is certain to be newsworthy!

The five-day event will feature many cutting-edge lectures, corporate-sponsored workshops, and plenary sessions focusing on major areas of clinical molecular diagnostics. We hope that you find this year's meeting to be both informative and enjoyable.

Event Information
Dates: November 14-18, 2023
Location: Salt Palace Convention Center | Salt Lake City, UT


Media Registration
We will be offering complimentary registration packages for contacts from qualified print, online, and broadcast news media outlets. Advance media registration for AMP's 2023 Annual Meeting & Expo opens Fall 2023. Members of the media will be required to provide appropriate media credentials and identification upon arrival. Contact Andrew Noble at for more information.


Media Guidelines

Preliminary Program - Please check back soon!


Andrew Noble
AMP Media Relations
Tel: 415-722-2129


About AMP

The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,600+ members practice in the various disciplines of molecular diagnostics, including bioinformatics, infectious diseases, inherited conditions, and oncology. They include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence policy and regulation on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit Follow AMP on Twitter: @AMPath.